Cancer vaccine - SynthRx

Drug Profile

Cancer vaccine - SynthRx

Latest Information Update: 13 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytRx Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 11 Apr 2011 SynthRx has been acquired by ADVENTRX Pharmaceuticals
  • 11 Apr 2011 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 29 Oct 2003 CytRx's cancer vaccine has been licensed to SynthRx worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top